Upstream Bio (UPB) Total Non-Current Liabilities (2023)
Upstream Bio's quarterly Total Non-Current Liabilities came in at $6.5 million in Q4 2023.
Upstream Bio has reported Total Non-Current Liabilities for 1 years, with the latest figure at $6.5 million in Q4 2023.
- For the quarter ending Q4 2023, Total Non-Current Liabilities changed N/A year-over-year to $6.5 million; the trailing twelve-month figure through Dec 2023 stood at $6.5 million (changed N/A YoY), and the FY2023 full-year result was $6.5 million, changed N/A from the prior year.
- Total Non-Current Liabilities for Q4 2023 stood at $6.5 million.
- The five-year high for Total Non-Current Liabilities was $6.5 million in Q4 2023, with the low at $6.5 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Upstream Bio | 454.22 Mn | 454.22 Mn | -3.94 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 6.52 Mn |